For patients with chronic obstructive ... a twice-daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once-daily dry powder inhaler for treatment of COPD in routine clinical ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

When you have COPD, medications can go a long way to help you breathe more easily and boost your quality of life. When you have moderate to severe disease, you and your doctor will work together ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Chronic Obstructive Pulmonary Disease (COPD) and emphysema are debilitating conditions that can make even simple tasks like walking or climbing stairs feel insurmountable. For many in the Texas ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.